---
layout: default
title: Vincristine
parent: 僅模型預測 (L5)
nav_order: 353
evidence_level: L5
indication_count: 3
---

# Vincristine
{: .fs-9 }

證據等級: **L5** | 預測適應症: **3** 個
{: .fs-6 .fw-300 }

---

## 目錄
{: .no_toc .text-delta }

1. TOC
{:toc}

---

<div id="pharmacist">

## 藥師評估報告

</div>

Based on the Evidence Pack, I'll now generate the evaluation report following the specified format.

---

# Vincristine: From Leukemia and Lymphoma to Ganglioneuroblastoma

## One-Sentence Summary

Vincristine is a vinca alkaloid cytotoxic agent widely established as backbone chemotherapy for acute leukemia, lymphoma, and pediatric solid tumors, though it currently holds no Philippines FDA registration.
The TxGNN model predicts it may be effective for **Ganglioneuroblastoma**,
with **4 clinical trials** and **6 publications** currently supporting this direction.

---

## Quick Overview

| Item | Content |
|------|---------|
| Original Indication | Not registered in the Philippines; globally established use in leukemia, lymphoma, and pediatric solid tumors |
| Predicted New Indication | Ganglioneuroblastoma |
| TxGNN Prediction Score | 99.31% |
| Evidence Level | L2 |
| Philippines Market Status | Not marketed |
| Number of Registrations | 0 |
| Recommended Decision | Proceed with Guardrails |

---

## Why is This Prediction Reasonable?

Currently, detailed mechanism of action data is not available in this Evidence Pack. Based on established pharmacological knowledge, Vincristine is a vinca alkaloid that inhibits microtubule polymerization by binding to β-tubulin, thereby disrupting mitotic spindle formation and inducing G2/M cell cycle arrest followed by apoptosis. Because this mechanism directly targets actively dividing cells, tumors with high mitotic rates are inherently sensitive to vincristine.

Ganglioneuroblastoma (GNB) originates from neural crest cells and sits within the neuroblastoma (NBL) differentiation spectrum. These tumors share key proliferative drivers with neuroblastoma — including MYCN amplification and ALK mutations — that sustain rapid cell division. This biological overlap makes vincristine's anti-mitotic mechanism directly applicable, and GNB is routinely co-enrolled in high-risk neuroblastoma clinical trials where vincristine forms a core component of the induction chemotherapy backbone.

The TxGNN prediction therefore reflects existing clinical practice rather than purely speculative repurposing. Multiple ongoing Phase 3 trials (NCT03126916, NCT06172296) explicitly include ganglioneuroblastoma within their high-risk neuroblastoma populations, and at least one Phase 2 pilot trial (NCT03786783) directly evaluates a vincristine-containing induction regimen in this population. The prediction score of 99.31% is consistent with this well-established mechanistic and clinical overlap.

---

## Clinical Trial Evidence

| Trial Number | Phase | Status | Enrollment | Key Findings |
|---------|------|------|------|---------|
| [NCT03786783](https://clinicaltrials.gov/study/NCT03786783) | Phase 2 | Active, Not Recruiting | 42 | Pilot trial evaluating dinutuximab + GM-CSF combined with induction chemotherapy for high-risk neuroblastoma/GNB; vincristine is a core component of the induction backbone — the most directly relevant trial for this indication |
| [NCT03126916](https://clinicaltrials.gov/study/NCT03126916) | Phase 3 | Recruiting | 750 | ¹³¹I-MIBG or lorlatinib added to intensive multimodal therapy (COG ANBL series, vincristine-containing induction) for newly diagnosed high-risk neuroblastoma/ganglioneuroblastoma |
| [NCT06172296](https://clinicaltrials.gov/study/NCT06172296) | Phase 3 | Recruiting | 478 | Dinutuximab added to intensive induction therapy for newly diagnosed high-risk neuroblastoma; vincristine serves as induction control arm backbone |
| [NCT01798004](https://clinicaltrials.gov/study/NCT01798004) | Phase 1 | Completed | 150 | Myeloablative busulfan/melphalan consolidation following vincristine-containing induction chemotherapy for newly diagnosed high-risk neuroblastoma (including GNB nodular subtype) |

---

## Literature Evidence

| PMID | Year | Type | Journal | Key Findings |
|------|-----|------|------|---------|
| [31342649](https://pubmed.ncbi.nlm.nih.gov/31342649/) | 2019 | Prospective Clinical Trial | Pediatric Blood & Cancer | Japan Children's Cancer Group (JN-L-10) prospective trial using image-defined risk factors to guide surgical timing in low-risk neuroblastoma/GNB; supports risk-adapted management strategy |
| [7421294](https://pubmed.ncbi.nlm.nih.gov/7421294/) | 1980 | Retrospective Case Series | J Thoracic and Cardiovascular Surgery | 31 patients with isolated intrathoracic ganglioneuroblastoma followed up to 25 years; surgery, radiotherapy, and chemotherapy all evaluated as treatment modalities |
| [8255850](https://pubmed.ncbi.nlm.nih.gov/8255850/) | 1993 | Case Report | Postgraduate Medical Journal | Unresectable spinal ganglioneuroblastoma achieving **histologically proven complete remission** with combination chemotherapy including vincristine (+ doxorubicin, cyclophosphamide, etoposide, ifosfamide, cisplatin) — no radiotherapy required |
| [15701990](https://pubmed.ncbi.nlm.nih.gov/15701990/) | 2005 | Case Report | J Pediatric Hematology/Oncology | Ganglioneuroblastoma presenting with obstructive jaundice; treated with chemotherapy explicitly including vincristine, cisplatin, pirarubicin, and cyclophosphamide with documented response |
| [8888754](https://pubmed.ncbi.nlm.nih.gov/8888754/) | 1996 | Case Report | J Pediatric Hematology/Oncology | Stage 4 multifocal ganglioneuroblastoma with rare gastric involvement in a female infant; documents clinicopathological characteristics |
| [3071124](https://pubmed.ncbi.nlm.nih.gov/3071124/) | 1988 | Case Report | Acta Urologica Japonica | Adult adrenal ganglioneuroblastoma with giant regional lymph node metastasis in a 21-year-old; multimodality treatment including chemotherapy documented |

---

## Philippines Market Information

Vincristine is currently **not registered** in the Philippines. No FDA Philippines licenses are on record (total registrations: 0). Any clinical use would require special import authorization or compassionate use approval from the Philippines FDA.

---

## Cytotoxicity

| Item | Content |
|------|---------|
| Cytotoxicity Classification | Conventional cytotoxic — Vinca alkaloid class (microtubule inhibitor) |
| Myelosuppression Risk | Moderate; primarily leukopenia; thrombocytopenia and anemia less pronounced compared to other cytotoxics |
| Emetogenicity Classification | Low to minimal |
| Monitoring Items | CBC with differential (each cycle), neurological assessment for peripheral neuropathy (dose-limiting toxicity), liver function tests (hepatic CYP3A4 metabolism), constipation/ileus surveillance |
| Handling Protection | Must follow cytotoxic drug handling regulations; **critical safety alert**: intrathecal administration is uniformly fatal — must follow ISMP and WHO mandatory labeling/dispensing safeguards for vincristine (dedicated "For IV Use Only" overwrap) |

---

## Safety Considerations

Please refer to the package insert for safety information.

> Philippines FDA package insert data, label warnings, and contraindications were not available in this Evidence Pack. Drug interaction data was also not retrievable (DDI query returned no results). A full safety review obtaining the approved product monograph is required before any clinical use consideration.

---

## Conclusion and Next Steps

**Decision: Proceed with Guardrails**

**Rationale:**
Vincristine is already embedded as standard induction chemotherapy in multiple active Phase 3 trials that explicitly enroll ganglioneuroblastoma patients within high-risk neuroblastoma cohorts, and case reports document complete remission in GNB treated with vincristine-containing regimens. The prediction reflects established clinical practice; the primary barrier to use in the Philippines is the lack of local registration, not insufficient evidence.

**To proceed, the following is needed:**
- Philippines FDA registration or special import/compassionate use authorization (drug currently not marketed locally)
- Full safety review: obtain and parse Philippines FDA-approved or internationally recognized package insert for warnings, contraindications, and drug-drug interactions
- Mechanism of action documentation via DrugBank API query (DG002 remediation)
- Formal pharmacovigilance and risk management plan for cytotoxic agent use, with special attention to pediatric dosing protocols
- Mandatory intrathecal error prevention protocol: implement ISMP-recommended "For IV Use Only" overwrap and separate dispensing workflow before any institutional use
## Disclaimer

This content is for research purposes only and does not constitute medical advice.
Clinical validation is required before any clinical application.

---

